What is he best known for?
The fields of study he is best known for:
Paolo M. Comoglio mostly deals with Hepatocyte growth factor, Receptor tyrosine kinase, Tyrosine kinase, Cancer research and Cell biology.
To a larger extent, Paolo M. Comoglio studies Receptor with the aim of understanding Hepatocyte growth factor.
His Receptor tyrosine kinase research is multidisciplinary, incorporating elements of Hepatocyte Growth Factor Receptor, Proto-oncogene tyrosine-protein kinase Src, ROR1, Platelet-derived growth factor receptor and Growth factor receptor.
His research integrates issues of Molecular biology, Oncogene, C-Met and Myogenesis in his study of Tyrosine kinase.
His study explores the link between Cancer research and topics such as Cell surface receptor that cross with problems in Receptor Protein-Tyrosine Kinases.
His study in Cell biology is interdisciplinary in nature, drawing from both Semaphorin, Plexin and Cell adhesion.
His most cited work include:
- Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth (1230 citations)
- Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. (1064 citations)
- Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. (985 citations)
What are the main themes of his work throughout his whole career to date?
Paolo M. Comoglio mainly focuses on Cancer research, Cell biology, Molecular biology, Hepatocyte growth factor and Receptor tyrosine kinase.
His research on Cancer research also deals with topics like
- Receptor which intersects with area such as Cell,
- Cancer together with Immunology.
His biological study spans a wide range of topics, including Semaphorin and Lung cancer.
His studies deal with areas such as Cell culture, Biochemistry, Antigen, Rous sarcoma virus and Antibody as well as Molecular biology.
His Hepatocyte growth factor research includes elements of Growth factor, Paracrine signalling, Autocrine signalling and Cell growth.
The various areas that Paolo M. Comoglio examines in his Receptor tyrosine kinase study include Tyrosine kinase, Proto-oncogene tyrosine-protein kinase Src, ROR1, Platelet-derived growth factor receptor and Tyrosine phosphorylation.
He most often published in these fields:
- Cancer research (35.77%)
- Cell biology (27.34%)
- Molecular biology (25.84%)
What were the highlights of his more recent work (between 2011-2021)?
- Cancer research (35.77%)
- Cancer (10.67%)
- Cell biology (27.34%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Cancer research, Cancer, Cell biology, Lung cancer and Microtubule dynamics.
His Cancer research research is multidisciplinary, relying on both Receptor, Hepatocyte growth factor, Cancer cell, Targeted therapy and Kinase.
His Receptor study combines topics from a wide range of disciplines, such as Apoptosis and Programmed cell death.
His studies in Hepatocyte growth factor integrate themes in fields like Tumor microenvironment, Receptor tyrosine kinase and Paracrine signalling.
His Receptor tyrosine kinase research is included under the broader classification of Signal transduction.
He has researched Cancer in several fields, including Tyrosine kinase and Antibody, Immunology.
Between 2011 and 2021, his most popular works were:
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer (435 citations)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial (410 citations)
- Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis (189 citations)
In his most recent research, the most cited papers focused on:
His primary areas of study are Cancer research, Cancer, Hepatocyte growth factor, Receptor tyrosine kinase and Internal medicine.
Paolo M. Comoglio combines subjects such as Cetuximab, Tyrosine kinase, Phosphorylation, PI3K/AKT/mTOR pathway and Kinase with his study of Cancer research.
The study incorporates disciplines such as Lung cancer and Drug resistance in addition to Tyrosine kinase.
Paolo M. Comoglio interconnects Pharmacology and Cell fate determination in the investigation of issues within Hepatocyte growth factor.
His Receptor tyrosine kinase study focuses on Signal transduction and Receptor.
His research in Internal medicine intersects with topics in Endocrinology, Epigenetics, Oncology and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
